Chad Therapeutics Reports Increasing Sales.Business Editors CHATSWORTH, Calif.--(BUSINESS WIRE)--June 14, 2001 Chad Chad (chăd, chäd), Fr. Tchad, officially Republic of Chad, republic (2005 est. pop. 9,826,000), 495,752 sq mi (1,284,000 sq km), N central Africa. Therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. Inc. (AMEX AMEX See: American Stock Exchange :CTU CTU Colorado Technical University CTU Czech Technical University in Prague CTU Counter Terrorist Unit CTU Clinical Trials Unit CTU Catholic Theological Union CTU Chicago Teachers Union CTU Computer Training Unit CTU Control Unit ), producer and distributor of oxygen conserving con·serve v. con·served, con·serv·ing, con·serves v.tr. 1. a. To protect from loss or harm; preserve: devices and oxygen systems used by pulmonary pulmonary /pul·mo·nary/ (pool´mo-nar?e) 1. pertaining to the lungs. 2. pertaining to the pulmonary artery. pul·mo·nar·y adj. Of, relating to, or affecting the lungs. patients who need supplementary oxygen, today announced significantly increasing sales during the first quarter ending June 30, 2001. Thomas E. Jones, Chief Executive Officer, stated, "Sales in the current quarter, which will end on June 30, 2001, are running in excess of 50% above the prior year's quarter. If this sales performance continues through the balance of the quarter, we expect to make substantial progress this quarter towards our goal of returning to profitability. The current sales performance is further evidence that our turnaround strategy is producing positive results. The increase in sales continues to be driven by increased domestic sales in our oxygen conserver line, led by the new OXYMATIC(R) 400 series conservers, and international sales of the TOTAL O2(R) Delivery System. We believe this positive trend will be aided by additional products under development that are designed to further improve our competitive position." Jones further stated, "We continue to be pleased with the market reception the OXYMATIC 400 series conservers have received since their introduction last year. We believe our ability to regain market share in the conserver market has been fostered by CHAD's leadership in bringing state-of-the-art technology to the homecare market and our proven reputation for reliability in this area." The foregoing statements regarding prospects for the OXYMATIC 400 series conservers, the TOTAL O2 system and products under development are forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. that involve certain risks and uncertainties. The success of the OXYMATIC 400 series conservers, the TOTAL O2 system and products under development will depend on the health care community's perception of the products' capabilities and benefits, the degree of acceptance the products achieve among homecare providers, competition and, with respect to products under development, obtaining timely regulatory approval. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion